Implanet reported first quarter financial results, showing growth over the same period last year.
Here are five things to know:
1. The company reported a 3 percent increase in revenue in the first quarter. The Jazz activity increased 27 percent, which accounted for 52 percent of the total revenue. Last year in the first quarter, Jazz activity made up 42 percent of the total revenue.
2. The knee sales decreased 15 percent in the first quarter.
3. Jazz implant sales increased 61 percent in France and 3 percent in the United States. The company reported 60 percent growth in the high potential degenerative bone disorder segment in markets where the company operates directly; in this segment, the Jazz sales were responsible for 42 percent of sales.
4. In the first quarter, there were 2,032 Jazz implants sold, a 70 percent volume growth.
5. The company treated around 4,000 patients with its implants since the Jazz launch.
"For 2017, we remain confident in our ability to sustain continued growth in Jazz revenue and establish it as a benchmark in spine surgery," said Ludovic Lastennet, CEO of Implanet. "Regarding the knee segment, we expect activity to stabilize during the second quarter of 2017."